News

Video: Global Fund Impact in Indonesia

The Global Fund to fight AIDS, Tuberculosis and Malaria has had a positive impact in Indonesia helping the country leverage local and national funding for its programmes. The video presents interviews with a diverse range of stakeholders and touches on issues around financial accountability, the need for programme implementers to have more training to manage TB, HIV or malaria programs, raises fears of people living with HIV about starting on anti-retroviral therapy and adhering to treatment and presents views on the scaling up treatment to meet MDGs targets.

Another perspective from Kenya:

Spotlight: Mixed perceptions of the Global Fund in Kenya by Henry Neondo, Kenya

Funding for health should begin targeting prevention programmes that address issues that affect women and children, and the Global Fund to fight HIV/AIDS, TB and Malaria (The Global Fund) has a key role to play.

In the context of HIV, Professor Alloys Orago, Director of the National AIDS Control Council (NACC), says “for every one person put on treatment, two more get newly infected – women and the youth still bearing the brunt of the three most burdened some diseases: HIV, tuberculosis and malaria.”

For full text to article by , click here.

More News
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...